| A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants SC Sim, C Risinger, ML Dahl, E Aklillu, M Christensen, L Bertilsson, ... Clinical Pharmacology & Therapeutics 79 (1), 103-113, 2006 | 737 | 2006 |
| Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. E Aklillu, I Persson, L Bertilsson, I Johansson, F Rodrigues, ... Journal of pharmacology and experimental therapeutics 278 (1), 441-446, 1996 | 462 | 1996 |
| Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population MG Scordo, E Aklillu, U Yasar, ML Dahl, E Spina, M Ingelman‐Sundberg British journal of clinical pharmacology 52 (4), 447-450, 2001 | 260 | 2001 |
| Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans R Ghotbi, M Christensen, HK Roh, M Ingelman-Sundberg, E Aklillu, ... European journal of clinical pharmacology 63 (6), 537-546, 2007 | 217 | 2007 |
| Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1 E Aklillu, JA Carrillo, E Makonnen, K Hellman, M Pitarque, L Bertilsson, ... Molecular pharmacology 64 (3), 659-669, 2003 | 208 | 2003 |
| Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population E Aklillu, M Oscarson, M Hidestrand, B Leidvik, C Otter, ... Molecular pharmacology 61 (3), 586-594, 2002 | 174 | 2002 |
| 4β-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians U Diczfalusy, J Miura, HK Roh, RA Mirghani, J Sayi, H Larsson, KG Bodin, ... Pharmacogenetics and genomics 18 (3), 201-208, 2008 | 138 | 2008 |
| A novel polymorphism in ABCB1 gene, CYP2B6* 6 and sex predict single‐dose efavirenz population pharmacokinetics in Ugandans JK Mukonzo, D Röshammar, P Waako, M Andersson, T Fukasawa, ... British journal of clinical pharmacology 68 (5), 690-699, 2009 | 112 | 2009 |
| Long‐term efavirenz autoinduction and its effect on plasma exposure in HIV patients E Ngaimisi, S Mugusi, OM Minzi, P Sasi, KD Riedel, A Suda, N Ueda, ... Clinical Pharmacology & Therapeutics 88 (5), 676-684, 2010 | 105 | 2010 |
| Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype Z Jiang, N Dragin, LF Jorge-Nebert, MV Martin, FP Guengerich, E Aklillu, ... Pharmacogenetics and genomics 16 (5), 359-367, 2006 | 103 | 2006 |
| S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians I Persson, E Aklillu, F Rodrigues, L Bertilsson, M Ingelman-Sundberg Pharmacogenetics 6 (6), 521-526, 1996 | 96 | 1996 |
| Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa … E Ngaimisi, A Habtewold, O Minzi, E Makonnen, S Mugusi, W Amogne, ... PloS one 8 (7), e67946, 2013 | 92 | 2013 |
| Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients G Yimer, N Ueda, A Habtewold, W Amogne, A Suda, KD Riedel, ... PLoS One 6 (12), e27810, 2011 | 90 | 2011 |
| Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes N Djordjevic, R Ghotbi, L Bertilsson, S Jankovic, E Aklillu European journal of clinical pharmacology 64 (4), 381-385, 2008 | 87 | 2008 |
| Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2− 163C> A polymorphism N Djordjevic, R Ghotbi, S Jankovic, E Aklillu European journal of clinical pharmacology 66 (7), 697-703, 2010 | 85 | 2010 |
| High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a … G Yimer, W Amogne, A Habtewold, E Makonnen, N Ueda, A Suda, ... The pharmacogenomics journal 12 (6), 499, 2012 | 81 | 2012 |
| Towards host-directed therapies for tuberculosis A Zumla, J Chakaya, M Hoelscher, F Ntoumi, R Rustomjee, C Vilaplana, ... Nature reviews Drug discovery 14 (8), 511, 2015 | 80 | 2015 |
| CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population RA Mirghani, J Sayi, E Aklillu, A Allqvist, M Jande, A Wennerholm, ... Pharmacogenetics and genomics 16 (9), 637-645, 2006 | 80 | 2006 |
| Keratin‐18 and micro RNA‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohorts P Thulin, G Nordahl, M Gry, G Yimer, E Aklillu, E Makonnen, G Aderaye, ... Liver international 34 (3), 367-378, 2014 | 77 | 2014 |
| Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden E Aklillu, K Herrlin, LL Gustafsson, L Bertilsson, M Ingelman-Sundberg Pharmacogenetics and Genomics 12 (5), 375-383, 2002 | 77 | 2002 |
